Does Valproic Acid Deplete Biotin? What the Research Says

Yes, valproic acid depletes biotin (vitamin B7), and this interaction is clinically relevant for long-term users. Valproic acid interferes with biotin recycling by inhibiting biotinidase, the enzyme responsible for recovering biotin from dietary proteins and from the body's own biotinylated enzymes. Without efficient recycling, biotin is lost through normal metabolic turnover faster than it can be replaced by diet alone. Approximately 50% of patients on chronic valproic acid therapy develop measurable biotin insufficiency. The depletion is typically subclinical, meaning blood tests may catch it before symptoms appear, but it can contribute to hair thinning, skin rashes, and impaired fatty acid metabolism that are often attributed to valproic acid's direct side effects.

PubMed indexes 3,337 articles related to valproic acid, with 15 meta-analyses evaluating its safety profile and metabolic effects. Biotinidase activity assays in patients on chronic valproic acid therapy consistently demonstrate reduced enzyme function compared to untreated controls. Urinary excretion of 3-hydroxyisovaleric acid (3-HIA), a functional marker of biotin insufficiency, is elevated in a significant proportion of valproic acid users, confirming impaired biotin-dependent carboxylase activity. The CTD knowledge graph tracks valproic acid interactions across extensive gene networks, including multiple pathways where biotin serves as a cofactor. FAERS adverse event reports include alopecia, dermatitis, and metabolic symptoms in valproic acid users that overlap with classic biotin deficiency presentations. These symptoms improve with biotin supplementation, supporting a causal rather than coincidental relationship.

Valproic acid depletes biotin through two complementary mechanisms. First, it competitively inhibits biotinidase, the enzyme that cleaves biotin from biocytin (biotinyl-lysine) during protein digestion and during normal intracellular enzyme turnover. The body normally recycles most of its biotin rather than relying entirely on dietary intake, and valproic acid disrupts this efficient recycling system. Second, valproic acid undergoes beta-oxidation in the liver, a process that may compete with biotin-dependent carboxylases (acetyl-CoA carboxylase, propionyl-CoA carboxylase, pyruvate carboxylase, and 3-methylcrotonyl-CoA carboxylase) for available biotin cofactor pools. These carboxylases are essential for fatty acid synthesis, gluconeogenesis, and amino acid metabolism. When biotin levels drop, the activity of all four carboxylases declines, producing metabolic disturbances that can be detected through organic acid testing in urine.

If you take valproic acid long-term, consider biotin supplementation at 10-30 mcg daily (significantly below the pharmacological doses used cosmetically). This amount is sufficient to offset valproic acid's effect on biotinidase without approaching levels that could interfere with lab tests. Important: high-dose biotin (above 5 mg daily) can interfere with thyroid function tests and troponin assays, producing falsely normal or abnormal results. Always inform your lab and healthcare provider if you take any biotin supplement. Request a biotinidase activity test or urinary 3-HIA levels as functional biotin status markers, since serum biotin alone can be unreliable. Biotin-rich foods include eggs, liver, almonds, sweet potatoes, and salmon. Avoid eating raw egg whites in large quantities, as avidin in raw whites binds biotin and reduces absorption.